Informed consent of Efficacy and safety of Binafuxi Granules in treating common cold with heat syndrome

Dear patients:

Before you decide whether or not to participate in this study, read the following as carefully as possible:

You are diagnosed with the common cold (heat syndrome). We invite you to participate in the phase II trial for Binafuxi Granules in treating the common cold with heat syndrome. This trial was approved by State Food and Drug Administration (No. 2014L01342). The objective is to evaluate the efficacy and safety of Binafuxi Granules in patients with the common cold with heat syndrome.

1. Research background

The common cold is one of most common upper respiratory tract infectious disease. It's mainly caused by viruses and the rhinovirus is the most common cause. Binafuxi granules, a traditional Uighur medicine, derived from the Uighur medicine ancient books, is manufactured by Xinjiang Yinduolan Uighur Medicine Co. Ltd., Xinjiang, China. It is mainly composed of Tianshanjincai (Viola tianshanica Maxim), Heguotenggen (Roots of Operculina Turpethum), Gancaojingao (Extractum Glycyrrhizae), Meiguihua (Flos Rosae Rugosae), Sikamoniyazhi (Resina Scammoniae) and Alihong (Sclerotium Fomitis Officinalis). Binafuxi Granules have the effect of clearing heat, relieving cough and reducing inflammation. The toxicity experiment showed that no adverse effects was found, when the dosage of Binafuxi Granules was equal to the normal clinical dosage or 15x normal dosage.

West China Hospital of Sichuan University, as the principal research institution in this trial, in response to delegation from Xinjiang Yinduolan Uighur Medicine Co. Ltd. , launched this trial along with Shanghai Traditional Chinese Medicine Hospital, Xinjiang Traditional Chinese Medicine Hospital, Ruikang Hospital Affiliated to Guangxi University of traditional Chinese medicine, Lishui People's Hospital to assess the efficacy and safety of Binafuxi Granules in treating the common cold with heat syndrome.

2. Eligible for this study

If you want to participate in this study, you need to meet the follows: (1) diagnosis of common cold according to Western medicine and symptom presenting within 24 hours; (2) diagnosis of common cold with heat syndrome according to traditional Uighur medicine; (3) with fever and body temperature between 38 degrees Celsius and 39 degrees Celsius; (4) aged between 18 and 65 years; (5) willing to participate and sign the informed consent.

3. Excluded from participates

If you meet one of the following, you will not be eligible to participate in this study: (1) patients with influenza, acute or chronic rhinitis, acute sinusitis, suppurative tonsillitis, pneumonia and Tuberculosis; (2) white blood cell count＞11.0×109/L and/or neutrophils percentage > 75%; (3) patients who are taking any medication to treat common cold; (4) liver function levels (alanine aminotransferase (ALT) and aspartate aminotransferase (AST)) 1.5 times higher than the upper limit of normal, abnormal serum creatinine; (5) patients with serious primary diseases of the cardiovascular, pulmonary, kidney, liver, neurological and hematological system; (6) pregnant women, lactating women, or women who have a birth plan; (7) patients with allergic constitution or being allergic to the study drug; (8) patients who are participating in or have participated in another drug clinical trial within the last 3 months; (9) patients who have been judged by the investigator as inappropriate to participate in the clinical trial.

4. **Research introduction**

Before you are recruited in this trial the following tests will be done by your physicians to verify your eligibility: inquiry of clinical history and symptoms, physical examination, blood routine test, urine routine test, stool test electrocardiogram, liver function test, kidney function test and chest X-ray. Female patients of childbearing age need to take a urine pregnancy test.

If you are eligible and voluntary, you will be randomly assigned to a high-dose group, low-dose group or placebo control group, in which you will take Binafuxi Granules 2 packages (5.5g) twice daily, Binafuxi Granules 1 package (2.75g) plus placebo 1 package (2.75g) twice daily, or placebo 2 packages (5.5g) twice daily, respectively. All drugs will be

dissolved in 200 ml warm water and taken orally 2 times daily for 3 days. The follow-up visits last 1 day after the treatment.

During the study, if your body temperature rises to higher than 39.0°C and/or your temperature do not drop significantly at 48h post administration, you can use paracetamol to bring down a fever following doctor's advice.

You are expected to visit the physicians on the fourth day after the beginning of treatment, when your physicians will review and record information on your general conditions, clinical symptoms and signs. What calls for special attention is that you should come to visit your physicians with an empty stomach on the fourth day in order to do some laboratory examinations, such as routine blood test, urine analysis, stool test, blood electrolytes, liver function test (ALT, AST, ALP, TBil, and GGT) renal function test (BUN, serum creatinine, microalbuminuria, urinary nag enzyme and serum cystatin C) and electrocardiogram.

5. Benefits and risks

You are entitled to free drug medications and relevant examinations. The primary benefit may be the improvement of your disease condition, which could not be guaranteed of course. Treatment may end up with no effect or even deterioration, which is the risk every patient may encounter. Your physicians will stop the study on you and provide some effective therapies for you if your condition is worse. At the end of trial, you will get the travel allowance.

Although obvious adverse effects of Binafuxi granules have not been observed to date, some unreported or unpredicted side effects and discomforts may happen in your treatment process. Please inform your physicians as soon as possible whenever you experience any unwell or something unexpected occur to you, regardless the relationship between the unwell or incidence and the test drugs. In this case, you will be properly treated by your physicians. When the serious adverse events related to test drugs occur, the sponsor will bear all the legal responsibilities, treatment expenses, and compensations.

6. Adverse

No obvious adverse effect was found in previous clinical practice and animal tests.

7. Is my personal information confidential?

Your personal medical record will be preserved in hospital. Main investigators, representative of sponsors, ethical committees and drug regulation agencies are allowed to read your researching data. Your personal identity will never be disclosed to any one in the result dissemination and publication. We will try our best to protect your individual privacy to the extent permitted by law.

8. You are free to involving or withdraw

The trial is conducted in accordance with the Declaration of Helsinki (2008) and the Good Clinical Practice Guidelines. And it was approved by the Clinical Trials and Biomedical Ethics Committee of West China Hospital of Sichuan University. Your rights and interests in this study will be protect.

Involvement is totally voluntary. You are free to pull back on taking part in the trial and drop out of the trial during the process at any time. Every decision that you make will totally unlikely to influence the relationship between you and your doctor, or your health care, or cause a loss to other aspects for you. Your doctor or investigator in the trial is probably to inform you a notice of termination for your best interests. You will be asked for some information about researching drugs once you quit from the trial. Your will be requested to complete relevant physical examinations and chemical tests if necessary.

9. How to obtain more information about the trial?

You can raise your questions about the current trial at any time. Your doctor will give you his/her phone number in order to reply to your questions in convenience. Anything new information that affect your decision will be explained by your doctor in time.

10. What is supposed to be doing now?

You are expected to make decision by yourself. You could discuss with your family or friends if necessary. Do not sign this form until you have fully understood this research.

Thank you for reading this consent. Notify your doctor if you have a preference of taking part in the trial. Your doctor will arrange for you.

Please keep this consent.

Signature Page

Study: Efficacy and safety of Binafuxi Granules in treating common cold with heat syndrome: a multicenter, double-blind, placebo-controlled and randomized phase II clinical trial

Sponsor: Xinjiang Yinduolan Uighur Medicine Co. Ltd.

SFDA approved Number: 2014L01342

Declaration of Consent:

I have read all information given above. I have asked some questions about this trial and got satisfying replies to all of my questions from my doctors. I have been informed the risks and benefits in this trial. I know participation as subjects in this trial is voluntary. I have enough time to think about it and understand that:

1. As a subject, I will follow the instructions of informed consent.
2. My personal medical record will be only used in clinical research. My personal information is confidential and will be legally protected.
3. If I have an adverse effect related to test drugs, I will be actively treated by my doctor and the sponsor will pay for the costs of related treatment.
4. I am free to quit from the trial at any time and will not be subjected to discrimination or revenge, or unfair treatment on health care
5. I volunteers for this trial. I will fully cooperate with investigator.
6. I also clearly understand that I am expected to tell my doctors about my conditions

Patient signature: _____ Signature Date:_____ Phone number:_____

Investigator signature:_____Signature Date:_____Phone number:_____